Prostatype Genomics AB (DE:PGO0)
FRANKFURT:PGO0
PGO0 Stock Chart & Stats
€0.05
-€0.02(-2.92%)
At close: 4:00 PM EST
€0.05
-€0.02(-2.92%)
Day’s Range― - ―
52-Week Range€0.01 - €0.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€4.63M
Enterprise Value€19.11M
Total Cash (Recent Filing)€12.93M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding59,189,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€113.90K
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageThe company carries essentially zero recorded debt in 2025, which reduces solvency risk and interest burden over the medium term. Low leverage provides financial flexibility to raise capital if needed and reduces refinancing pressure while the business works to scale commercial revenues.
Specialized Diagnostic OfferingProstatype's focus on a prognostic test for prostate cancer reflects a specialized product-market fit in clinical decision support. A molecular biomarker plus clinical-parameter approach creates a defensible niche versus generic diagnostics and underpins repeatable test revenue and clinical adoption over time.
Improving Cash Burn TrendOperating cash burn has moderated in 2025 compared with 2024, indicating initial traction in controlling costs or modest revenue improvements. A declining burn rate is a durable operational improvement that extends runway and reduces near-term financing dependency while management pursues commercialization scale.
Bears Say
Small And Volatile Revenue BaseRevenue volatility and an absolute small revenue base limit operational leverage and make margin improvement difficult. A 17% year decline in 2025 versus 2024 signals inconsistent market adoption and raises the timeline for achieving scale necessary to absorb fixed costs and turn profitability durable.
Persistent Deep Losses And Negative MarginsSustained large operating losses and severely negative margins indicate the current cost structure far outpaces commercial revenues. Such persistent unprofitability erodes equity, constrains reinvestment capacity, and requires ongoing external funding until structural revenue or margin improvements are realized.
Weak Cash Generation Reliant On FinancingConsistent negative operating and free cash flow means the business cannot self-fund growth and must access external capital. Over the medium term this creates dilution or financing risk, and makes strategic planning dependent on successful funding or rapid improvement in per-test economics and volume.
PGO0 FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was €0.01 and its highest was €0.20 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is €4.63M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 13, 2026 which is in 130 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -€0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.036.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 59,189,320 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -€0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in DE:PGO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. It offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, Gleason Score, and Tumor Stage, as well as calculates the P-score. The test is based on database containing prostate cancer patients and provides decision support for patients and doctors when making a treatment decision. The company was founded in 2007 and is based in Solna, Sweden.